反応式
N1C2C(=CC=CC=2)C=N1.[CH2:10]([N:17]1[C:25]2[C:20](=[CH:21][CH:22]=[CH:23][CH:24]=2)[C:19]([O:26][CH2:27][CH2:28][CH2:29][N:30]([CH3:32])[CH3:31])=[N:18]1)[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=1.CN(CCCOC1C2C=CC=CC=2N(CC2C=CC=CC=2)N=1)C.Cl.[Na].C(N1C2C(=CC=CC=2)C(O)=N1)C1C=CC=CC=1.[Cl:75]CCCN(C)C>C1(C)C(C)=CC=CC=1>[CH2:10]([N:17]1[C:25]2[C:20](=[CH:21][CH:22]=[CH:23][CH:24]=2)[C:19]([O:26][CH2:27][CH2:28][CH2:29][N:30]([CH3:31])[CH3:32])=[N:18]1)[C:11]1[CH:12]=[CH:13][CH:14]=[CH:15][CH:16]=1.[ClH:75]参加物
実験手順
As described in the aforementioned United States patent specification, indazole compounds embraced by the foregoing general formula II are biologically active in that some manifest analgesic, antiinflammatory and myorelaxing activity. Probably the best known of such compounds at the present time is 1-benzyl-3-[3-(dimethylamino)propoxy]-1H-indazole, commonly referred to as benzydamine, which in the form of the hydrochloride salt, is employed in chemotherapy as an analgesic, antipyretic and/or antiinflammatory agent. In this role, the benzydamine hydrochloride is asssociated in pharmaceutical compositions with pharmaceutically acceptable organic or inorganic, solid or liquid carriers. According to the process described in the aforementioned United States specification, this compound is prepared by heating the sodium salt of 1-benzyl-3-hydroxy-1H-indazole with 3-chloropropyldimethylamine in xylene as an inert solvent. Treatment of the 1benzyl-3-[3-(dimethylamino)propoxy]-1H-indazole so-obtained with ethereal hydrochloric acid yields the corresponding hydrochloride salt, with a melting point of 160°C.
後処理
- customthis compound is prepared
出典と根拠
- ORDレコード
- ord-50f874291df4493cb6cbb0d2eb9897fd
- 出典データセット
- uspto-grants-1976_06
- 特許番号
- US03966761
関連ノート
読み込み中…